The U.S. Department of Justice last week issued a new directive on combating white-collar fraud that expressly names the Federal Food, Drug, and Cosmetic Act — putting pharmaceutical and device manufacturers, not just care providers, squarely within the enforcement perimeter of the agency's National Fraud Enforcement Division.

The move marks a shift in targeting. Historically, DOJ health fraud cases have centered on providers, clinics, home health agencies, and hospices. By explicitly citing the federal law that tightly regulates the pharmaceutical industry, the directive signals a broader set of corporate defendants.

"This is a subtle but significant expansion of their jurisdiction," said Kevin Lowell, a member of the Miller & Chevalier law firm. Lowell spent a decade at the DOJ, most recently as a deputy chief in the health care fraud section of the National Fraud Enforcement Division.

Why the wording matters

The directive's language determines which statutes the division prioritizes. Including the Food, Drug, and Cosmetic Act means conduct specific to drug and device makers — matters governed by that statute rather than by billing or claims fraud frameworks — now sits closer to the center of the agency's white-collar fraud agenda.

For legal and compliance teams at life sciences companies, the practical consequence is exposure. Cases that previously would have been handled through other channels or agencies may now draw the attention of a fraud enforcement unit with a record of pursuing health care fraud.

What does this change for R&D and compliance portfolios?

The directive does not create new law. It reshapes enforcement emphasis within existing statutes. But for companies weighing portfolio decisions, the signal matters:

• Regulatory violations tied to drug and device statutes may increasingly be framed as fraud matters.
• Enforcement risk assessments that focused on billing practices now need to account for product-related statutory exposure.
• Compliance budgets may need rebalancing toward Food, Drug, and Cosmetic Act issues, given the division's expanded stated remit.

As Lowell's assessment suggests, the change is subtle in legal terms but significant in practical ones. A former senior official within the very division issuing the directive reads it as an expansion of jurisdiction — a data point that compliance officers and general counsel at manufacturers should weigh accordingly.

What comes next

The full scope of the directive and how aggressively the National Fraud Enforcement Division acts on it will become clear only in the cases the agency brings. Companies in the pharmaceutical and device sectors should watch those enforcement actions closely, as they will define the real-world boundaries of the agency's newly stated mandate.